There are 11 resources available
The Present State-of-the-art of Immune Check Point Inhibitors in Oncology
Presenter: J.B.A.G. Haanen, NL
Session: Welcome and Introduction
Resources:
Slides
Webcast
Is there a Clear Correlation Between PD-L1 Expression and Outcome? The Medical Oncologist Point of View
Presenter: M. Reck, DE
Session: Session 1 Patient selection
Resources:
Slides
Webcast
Strengths and Weaknesses of PD-L1 Testing: the Pathologist Point of View
Presenter: K. Kerr, UK
Session: Session 1 Patient selection
Resources:
Slides
Webcast
Immunogram, Immunoprofiling, Immunoscores and Other Biomarkers of Potential Use
Presenter: J. B.A.G. Haanen, NL
Session: Session 1 Patient selection
Resources:
Slides
Webcast
ESMO Guidelines: Management of Toxicities from Immune Check Point Inhibitors
Presenter: J. B.A.G. Haanen, NL
Session: Session 2 Immune-related toxicities
Resources:
Slides
Webcast
Patients with Brain Metastases
Presenter: M. Preusser, AT
Session: Session 3 Special situations
Resources:
Slides
Webcast
Patients with Liver Metastases or Liver Primary Tumours
Presenter: E. Martinelli, IT
Session: Session 3 Special situations
Resources:
Slides
Webcast
Patients with Previous Organ Transplant
Presenter: S. Champiat, FR
Session: Session 3 Special situations
Resources:
Slides
Webcast
The Issue of Fast Progression
Presenter: S. Champiat, FR
Session: Session 3 Special situations
Resources:
Slides
Webcast
Are Patients Overdosed with the Present Recommendations?
Presenter: A. Marabelle, FR
Session: Session 4 Treatment delivery: dosing and duration
Resources:
Slides
Webcast